This page contains press release content distributed by XPR Media. Members of the editorial and news staff of the USA TODAY Network were not involved in the creation of this content.

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs

Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

SAN FRANCISCO, CA / ACCESS Newswire / June 11, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the first study site has been established for Jaguar’s field study of Canalevia-CA1, Jaguar’s U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

Jaguar has two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) in dogs and to expand the indication of crofelemer from CID in dogs to treatment of general, non-infectious diarrhea in dogs. The company is in discussions with potential partners to fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally.

“We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general, non-infectious diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in the U.S and/or globally. Forging a partnership for this purpose is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for the company this year.”

“Jaguar’s canine-focused business development efforts align with our ongoing business development efforts on the ‘human’ side of the company for crofelemer – the catalysts for which are the pathways discussed with the FDA to bring crofelemer to metastatic breast cancer patients, a population we feel meets the requirements for orphan drug status; and the prompt establishment of an expanded access program for crofelemer for the ongoing important unmet medical need of cancer therapy-related diarrhea in breast cancer patients; and the initial proof-of-concept results from the ongoing investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer in Abu Dhabi in pediatric patients with intestinal failure due to the orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). As recently announced, the initial proof-of-concept results of this IIT show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, collectively referred to as parenteral support, in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively.”

The objective of the prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs to support potential full FDA approval of the drug for this indication. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected to the control group.

As announced, Jaguar established a new Investigational New Animal Drug (INAD) file with the FDA’s Center for Veterinary Medicine for crofelemer to treat general, non-infectious diarrhea in dogs.

Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine general, non-infectious diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don’t have easy access to outdoor facilities is a significant problem for families with dogs.

Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.1 According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.

Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

About Canalevia®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

Important Safety Information About Canalevia®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S and/or globally, Jaguar’s expectation that the U.S. population of metastatic breast cancer patients meets the requirements for orphan drug status, Jaguar’s expectation that it will promptly establish an expanded access program for crofelemer for cancer therapy-related diarrhea in breast cancer patients, and Jaguar’s expectation that the field study of Canalevia-CA1 for the treatment of CID in dogs will support potential full FDA approval of the drug for this indication. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

1 “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@xpr.media

In Home Flooring’s Hardwood Experts Unveil Eco-Friendly Solutions for Flawless Floors

In Home Flooring’s Hardwood Experts Unveil Eco-Friendly Solutions for Flawless Floors

In Home Flooring, a company based in Denver, is renowned for its comprehensive services in providing high-quality flooring solutions. Their new plan to improve how…

July 22, 2025

Attempted Identity Theft is Still a Threat-Here’s What to Do Next

Attempted Identity Theft is Still a Threat-Here’s What to Do Next

An attempted identity theft is more than a close call-it’s a serious warning. With reports sharply rising, Petroff Amshen LLP explains how a timely Identity…

July 22, 2025

Optex Systems Announces an up to $10.2 Million Award for Optical Sighting System

Optex Systems Announces an up to $10.2 Million Award for Optical Sighting System

RICHARDSON, TX / ACCESS Newswire / July 22, 2025 / Optex Systems Holdings, Inc. (Nasdaq:OPXS), a leading manufacturer of precision optical sighting systems for domestic…

July 22, 2025

Q-Pixel Inc. Launches Its Breakthrough Q-Transfer Technology

Q-Pixel Inc. Launches Its Breakthrough Q-Transfer Technology

Industry breakthrough enabling high-yield (>99.9995%) microLED transfer LOS ANGELES, CA / ACCESS Newswire / July 22, 2025 / MicroLED display startup Q-Pixel Inc. has debuted…

July 22, 2025

New York-based Futurist Wins Dual Honors at The Speaker Awards 2025

New York-based Futurist Wins Dual Honors at The Speaker Awards 2025

Nikki Greenberg, a pioneering futurist and global authority on innovation in real estate, was named a Top 3 finalist in both the “Best AI &…

July 22, 2025

Toronto Central’s Ontario Business Central Inc. Receives 2025 Consumer Choice Award for Business Registration Services

Toronto Central’s Ontario Business Central Inc. Receives 2025 Consumer Choice Award for Business Registration Services

TORONTO, ONTARIO / ACCESS Newswire / July 22, 2025 / Ontario Business Central Inc., a trusted provider of online business registration, incorporation, and corporate filing…

July 22, 2025

The University of Florida, Florida A&M University, & Virginia Commonwealth University Sign Multi-Year Contracts for iFOLIO All-in-One Digital Marketing Platform

The University of Florida, Florida A&M University, & Virginia Commonwealth University Sign Multi-Year Contracts for iFOLIO All-in-One Digital Marketing Platform

ATLANTA, GA / ACCESS Newswire / July 22, 2025 / Three major universities – the University of Florida, Florida A&M University, and Virginia Commonwealth University…

July 22, 2025

Josh & Heidi get Real, Raw, Authentic; Heidi’s 18 Year Bipolar Misdiagnosis, Josh’s Arrest, Heidi’s Deadly Disease in Rehab, Relapses, Volatility

Josh & Heidi get Real, Raw, Authentic; Heidi’s 18 Year Bipolar Misdiagnosis, Josh’s Arrest, Heidi’s Deadly Disease in Rehab, Relapses, Volatility

Sober.Buzz Continues to be Recognized by Prominent Medical Organizations including the AMAA, the WPS division of the AMA and the SGNO, Josh and Heidi Decide…

July 22, 2025

Taste the Best Tom Kha Soups in Las Vegas at Kung Fu Thai & Chinese Restaurant

Taste the Best Tom Kha Soups in Las Vegas at Kung Fu Thai & Chinese Restaurant

Kung Fu Thai & Chinese Restaurant has announced some exciting updates to its menu. Known for its wide array of Thai and Chinese dishes, the…

July 22, 2025

Cataract Surgery in Sioux Falls, SD: Trusted Leaders in Surgical Excellence and Patient Care

Cataract Surgery in Sioux Falls, SD: Trusted Leaders in Surgical Excellence and Patient Care

For individuals seeking cataract surgery in Sioux Falls, Vance Thompson Vision continues to be a destination for advanced care, experienced surgeons, and exceptional outcomes. As…

July 22, 2025

Expert Cleaning Solutions in Indian Trail Unveils Tailored Cleaning Services for Safer Workspaces

Expert Cleaning Solutions in Indian Trail Unveils Tailored Cleaning Services for Safer Workspaces

Expert Cleaning Solutions, based in Indian Trail, North Carolina, has recently rolled out updates to its wide range of commercial cleaning services. This initiative reflects…

July 22, 2025

Garland Homeowners Rejoice: Lone Wolf Exteriors Brings Expert Window and Siding Replacement Services to The Doorstep

Garland Homeowners Rejoice: Lone Wolf Exteriors Brings Expert Window and Siding Replacement Services to The Doorstep

Lone Wolf Exteriors, a business based in the Dallas-Fort Worth area, is expanding its services to meet the rising demand from customers. The company is…

July 22, 2025

Mechelle Evans and Glo2Facial Partner to Deliver Red Carpet Facials at Pre Emmy Weeks Most Exclusive Gifting Suite

Mechelle Evans and Glo2Facial Partner to Deliver Red Carpet Facials at Pre Emmy Weeks Most Exclusive Gifting Suite

LAS VEGAS, NV / ACCESS Newswire / July 22, 2025 / Licensed Medical Aesthetician and skincare expert Mechelle Evans, founder of Glo By ME SKIN,…

July 22, 2025

The Takis Intense Nacho Tour: Zero Heat, Intensely Cheesy Cruise Experience to Set Sail First Weekend of August in Chicago

The Takis Intense Nacho Tour: Zero Heat, Intensely Cheesy Cruise Experience to Set Sail First Weekend of August in Chicago

The Free 21+ Pre-Festival Fan Experience Will Feature a Live Performance by BUNT. CHICAGO, ILLINOIS / ACCESS Newswire / July 22, 2025 / Takis® is…

July 22, 2025

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market ESTERO, FL / ACCESS Newswire /…

July 22, 2025

Transitioning to Tech During the AI Frenzy? Yellow Tail Tech Makes It Possible

Transitioning to Tech During the AI Frenzy? Yellow Tail Tech Makes It Possible

Yellow Tail Tech Offers a Clear Path for Career Changers to Thrive in an Era of Automation MARYLAND CITY, MD / ACCESS Newswire / July…

July 22, 2025

Dispatch CEO Andrew Leone: AI is Rerouting the Last Mile for Businesses

Dispatch CEO Andrew Leone: AI is Rerouting the Last Mile for Businesses

How agentic AI, dynamic infrastructure, and seamless integrations reshape enterprise logistics from the inside out, starting at the last mile. BLOOMINGTON, MN / ACCESS Newswire…

July 22, 2025

ICE App Launches in NY, Spreads Across Country

ICE App Launches in NY, Spreads Across Country

ICE’s Deputy Director Warns of “violence.” NEW YORK CITY, NEW YORK / ACCESS Newswire / July 22, 2025 / Coquí, a groundbreaking mobile app built…

July 22, 2025

Mediagenix Named an IDC Innovator in Media and Entertainment, 2025

Mediagenix Named an IDC Innovator in Media and Entertainment, 2025

BRUSSELS, BE / ACCESS Newswire / July 22, 2025 / Mediagenix, a global leader in smart content solutions to profitably connect the right content to…

July 22, 2025

Viemed Healthcare Announces Second Quarter 2025 Earnings Conference Call Details

Viemed Healthcare Announces Second Quarter 2025 Earnings Conference Call Details

LAFAYETTE, LA / ACCESS Newswire / July 22, 2025 / Viemed Healthcare, Inc. (the “Company” or “Viemed“) (NASDAQ:VMD), an in-home clinical care provider of post-acute…

July 22, 2025

Focus Universal Set to Launch Customer Testing for Revolutionary One-Click SEC Reporting Software

Focus Universal Set to Launch Customer Testing for Revolutionary One-Click SEC Reporting Software

ONTARIO, CA / ACCESS Newswire / July 22, 2025 / Focus Universal Inc. (NASDAQ:FCUV) (“Focus” or the “Company”), a provider of patented hardware and software…

July 22, 2025

Exxel Pharma Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Exxel Pharma Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

– Video webcast now available on-demand AURORA, CO / ACCESS Newswire / July 22, 2025 / Exxel Pharma (“Exxel” or the “Company”), a pharmaceutical company…

July 22, 2025

enVVeno Medical Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

enVVeno Medical Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

– Video webcast now available on-demand IRVINE, CA / ACCESS Newswire / July 22, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a…

July 22, 2025

iTolerance, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

iTolerance, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

– Video webcast now available on-demand MIAMI, FL / ACCESS Newswire / July 22, 2025 / iTolerance, Inc. (“iTolerance” or the “Company”), a biotechnology company…

July 22, 2025

JTC Team Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference Now Live

JTC Team Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference Now Live

– Video webcasts from participating companies now available here   FRENCHTOWN, NJ / ACCESS Newswire / July 22, 2025 / JTC Team (“JTC”), a fully…

July 22, 2025

SMX Establishes Treasury Subsidiary to Advance Digital Asset Strategy in Wake of GENIUS Act

SMX Establishes Treasury Subsidiary to Advance Digital Asset Strategy in Wake of GENIUS Act

Formation of Treasury Subsidiary Marks Strategic Expansion as GENIUS Act Spurs Acceleration of SMX’s Blockchain and Digital Asset Vision NEW YORK, NY / ACCESS Newswire…

July 22, 2025

Global Polymer Industries Redefines What’s Possible with Custom-Molded UHMW-PE

Global Polymer Industries Redefines What’s Possible with Custom-Molded UHMW-PE

Innovative Compression Molding Enables Complex Designs, Embedded Features, and Material Integration for OEMs Across Industries MADISON, SD / ACCESS Newswire / July 22, 2025 /…

July 22, 2025

ZTEST Electronics Inc. Engages Integral Wealth Securities As Market Maker

ZTEST Electronics Inc. Engages Integral Wealth Securities As Market Maker

NORTH YORK, ON / ACCESS Newswire / July 22, 2025 / ZTEST Electronics Inc. (“ZTEST” or the “Company“) (CSE:ZTE)(OTCID:ZTSTF) is pleased to announce it has…

July 22, 2025

Arrive AI Accelerates Growth with Post-Nasdaq Launch Hiring Initiative

Arrive AI Accelerates Growth with Post-Nasdaq Launch Hiring Initiative

INDIANAPOLIS, INDIANA / ACCESS Newswire / July 22, 2025 / Arrive AI (NASDAQ:ARAI) – a pioneering autonomous delivery network anchored by Arrive Points™ – is…

July 22, 2025

Celebrating Culinary Craft: Bacio Trattoria Wins 2025 Consumer Choice Award for Italian Restaurants in Barrie

Celebrating Culinary Craft: Bacio Trattoria Wins 2025 Consumer Choice Award for Italian Restaurants in Barrie

BARRIE, ONTARIO / ACCESS Newswire / July 22, 2025 / Bacio Trattoria, a family-run Italian and Roman restaurant known for its authentic, handmade cuisine, has…

July 22, 2025

Electrovaya Launches Multiple Battery System Products for New Robotic Vehicle Platforms with Three Leading OEMs

Electrovaya Launches Multiple Battery System Products for New Robotic Vehicle Platforms with Three Leading OEMs

Multiple battery system products launched for new robotic vehicle platforms for three distinct OEM customers with applications ranging from material handling to surveillance systems Part…

July 22, 2025

Avino Marks Another Quarter of Strong Production Results; Announces Date of Q2 Earnings Call

Avino Marks Another Quarter of Strong Production Results; Announces Date of Q2 Earnings Call

VANCOUVER, BC / ACCESS Newswire / July 22, 2025 / Avino Silver & Gold Mines Ltd. (TSX:ASM)(NYSE American:ASM)(FSE:GV6) a long-standing silver producer in Mexico, continued…

July 22, 2025

Real Time Technologies Rebrands as realtime, Ushering in a Bold New Era for the Leaders in Wireless Retail Technology

Real Time Technologies Rebrands as realtime, Ushering in a Bold New Era for the Leaders in Wireless Retail Technology

realtime caps off a remarkable and resilient year of growth and transformation MIAMI, FLORIDA / ACCESS Newswire / July 22, 2025 / Real Time Technologies,…

July 22, 2025

American Critical Minerals Announces Kenneth Taylor as Strategic Advisor to the Company and Launches Early Warrant Exercise Incentive Program

American Critical Minerals Announces Kenneth Taylor as Strategic Advisor to the Company and Launches Early Warrant Exercise Incentive Program

VANCOUVER, BC / ACCESS Newswire / July 22, 2025 / American Critical Minerals Corp. (“American Critical Minerals” or the “Company“) (CSE:KCLI)(OTCQB:APCOF)(Frankfurt:2P3) is pleased to announce…

July 22, 2025

New to The Street Episode #679 Airs Tonight on Fox Business Network

New to The Street Episode #679 Airs Tonight on Fox Business Network

Featuring Hapbee Technologies (HAPBF), Arrive AI (ARAI), FLOKI, BioVie Pharma (BIVI) & The Sustainable Green Team (SGTM) NEW YORK, NY / ACCESS Newswire / July…

July 21, 2025

Hyper3D Unveils Revolutionary Rodin AI Suite, Instantly Generating 3D Models from Text and Images

Hyper3D Unveils Revolutionary Rodin AI Suite, Instantly Generating 3D Models from Text and Images

Deemos Tech today announced the official launch of Rodin ProRefine, a revolutionary AI creation suite seamlessly integrated into its flagship Hyper3D platform. This release redefines 3D…

July 21, 2025

Ashley B. DiLiberto, Esq. of Survivors of Abuse PA Recognized as a Leading Hazing Sexual Abuse Attorney in Pennsylvania

Ashley B. DiLiberto, Esq. of Survivors of Abuse PA Recognized as a Leading Hazing Sexual Abuse Attorney in Pennsylvania

Philadelphia, PA — Ashley B. DiLiberto, Esq., founder of Survivors of Abuse PA, has been recognized by ChatGPT as one of Pennsylvania’s top attorneys for…

July 21, 2025

J&P Coatings Introduces Revolutionary Duralast® Polyaspartic Coating Service to Greater Cleveland Homeowners and Businesses

J&P Coatings Introduces Revolutionary Duralast® Polyaspartic Coating Service to Greater Cleveland Homeowners and Businesses

Advanced concrete coating solution offers 5x stronger protection than traditional epoxy with same-day installation for garage floors, basements, and commercial spaces MIDDLEFIELD, OH, June 20,…

July 21, 2025

Cataract Surgery in Bozeman, MT: Trusted Expertise from Leaders in Vision Correction

Cataract Surgery in Bozeman, MT: Trusted Expertise from Leaders in Vision Correction

For those seeking cataract surgery in Bozeman, Vance Thompson Vision offers a high level of surgical expertise supported by years of research, innovation, and clinical…

July 21, 2025

Go Industries Unveils Groundbreaking GMC Grille Guard With Integrated Winch for Ultimate Truck Protection

Go Industries Unveils Groundbreaking GMC Grille Guard With Integrated Winch for Ultimate Truck Protection

Go Industries Inc., a well-established provider of solutions for trucks, law enforcement, and custom manufacturing, is launching its latest product: the Winch Grille Guards System….

July 21, 2025